Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | SLC22A2 | O15244 | 3/20 | 0.49 |
| ▸ | SLC47A2 | Q86VL8 | 3/20 | 0.49 |
| ▸ | SLC47A1 | Q96FL8 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | ATP4A | P20648 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ATP4B | P51164 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10367343 | 0.87 | HRH2 (0.77) | HRH2CYP3A4CYP2D6MAPTLMNA | |
| SCHEMBL11360309 | 0.85 | CYP3A4 (0.74) | HRH2CYP3A4CYP2D6MAPTLMNA | |
| SCHEMBL11357836 | 0.84 | CYP3A4 (0.72) | HRH2CYP3A4CYP2D6MAPTLMNA | |
| SCHEMBL11357832 | 0.84 | CYP3A4 (0.72) | HRH2CYP3A4CYP2D6MAPTLMNA | |
| SCHEMBL11373962 | 0.84 | CYP3A4 (0.72) | HRH2CYP3A4CYP2D6MAPTLMNA | |
| SCHEMBL11364135 | 0.84 | CYP3A4 (0.72) | HRH2CYP3A4CYP2D6MAPTLMNA | |
| Tiotidine SCHEMBL118501 | 0.83 | HRH2 (0.71) | HRH2CYP3A4CYP2D6MAPTLMNA | |
| SCHEMBL29388919 | 0.83 | CYP2D6 (0.71) | HRH2CYP3A4CYP2D6MAPTLMNA | |
| SCHEMBL11353503 | 0.83 | CYP3A4 (0.70) | HRH2CYP3A4CYP2D6MAPTLMNA | |
| SCHEMBL11353499 | 0.83 | CYP3A4 (0.70) | HRH2CYP3A4CYP2D6MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12415790-B2 | GluN2B-subunit selective antagonists of the N-methyl-D-aspartate receptors with enhanced potency at acidic pH | EMORY UNIVERSITY (US) | 2025-09-16 | — | — | US | disclosed |
| WO-2025137730-A1 | N-SUBSTITUTED TRYPTAMINES AND N-SUBSTITUTED LYSERGAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4543833-A1 | N-SUBSTITUTED PHENYLALKYLAMINES AND THEIR USE AS THERAPEUTIC AGENTS | Alexander Shulgin Research Institute, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20240400528-A1 | GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PH | NEUROP, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240360091-A1 | GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PH | NEUROP, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-4395783-A1 | GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PH | Emory University (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024006226-A1 | N-SUBSTITUTED PHENYLALKYLAMINES AND THEIR USE AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230349922-A1 | H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer | UNIVERSITÉ DE STRASBOURG (FR) | 2023-11-02 | — | — | US | disclosed |
| EP-4196793-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | Université de Strasbourg (FR) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023034589-A1 | GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PH | EMORY UNIVERSITY (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2022034121-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | UNIVERSITÉ DE STRASBOURG (FR) | 2022-02-17 | — | — | WO | disclosed |
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
| EP-1239280-A2 | ElogDoct:A tool for lipophilicity determination in drug discovery basic and neutral compounds | Pfizer Products Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415790-B2 | GluN2B-subunit selective antagonists of the N-methyl-D-aspartate receptors with enhanced potency at acidic pH | GRIN2B, GRIN2C, GRIN2A | HRH2 559/4885CYP3A4 2252/4885CYP2D6 1450/4885 |
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | CNR2, CNR1, HCN3 | HRH2 124/4885CYP3A4 994/4885CYP2D6 630/4885 |
| US-20240400528-A1 | GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PH | GRIN2B, GRIN2C, GRIN2A | HRH2 473/4885CYP3A4 2251/4885CYP2D6 1620/4885 |
| US-20240360091-A1 | GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PH | GRIN2B, GRIN2C, GRIN2A | HRH2 473/4885CYP3A4 2251/4885CYP2D6 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.